Genmab — November 2015
-
hvis der er nogen sammenhæng mellem US biotech, USDDKK og GEN's generelle kursudvikling - så har vi virklig lagt i banken over de sidste 2-3 børsdage
-
no hope...Mon ikke at nogen investorer bare har den strategi, at de i flere selskaber køber op i god tid inden regnskab? For at smide på den eventuelle stigning umiddelbart før fremlæggelsen.
-
nu kommer der oven i købet en opjustering. Det er sgu svært at bevare pessimismen...
-
frederik - yup. kl 1800 her - http://edge.media-server.com/m/p/2v8q8m3u
-
personligt syntes jeg det er lidt skuffende, at ofa sc er udsat igenigen - men Novartis må jo mene det alvorligt, når de bruger så mange penge
-
tak for det sukkeralf
-
fra sibelius den 9/10 - We werein contact with Novartis yesterday and thecompanyconfirm that itplansto start twoph III trials in MS (likely RRMS and PPMS) in early 2016 and expectstolaunchthe drug inH2 2020.Novartis will pay low double-digit royalties(we expect 11-13%)to Genmab on sales.
-
castor fuldt rekrutteret
-
der er filet for dara rrmm
i canada
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind